Strategies to increase the reproducibility of protein fibrillization in plate reader assays

Analytical Biochemistry

Volumn 400, Issue 2, 2010, Pages 270-281

  Giehm, Lise ^a,b   Otzen, Daniel E ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

Aggregation; Amyloid; Fibril; Fibrillization; Glass beads; Plate reader; Reproducibility; SDS; Seeding; Shaking; SN

Indexed keywords

AGGLOMERATION; CLOUD SEEDING; DISEASE CONTROL; GLASS; GRANULAR MATERIALS; PROTEINS; RATE CONSTANTS; STATISTICS; SULFUR COMPOUNDS;

AMYLOID; FIBRIL; FIBRILLIZATION; GLASS BEAD; REPRODUCIBILITIES; SHAKING;

SODIUM DODECYL SULFATE;

ALPHA SYNUCLEIN; DODECYL SULFATE SODIUM; THIOFLAVINE;

AGITATION; ANALYTICAL PARAMETERS; ARTICLE; GROWTH RATE; INCUBATION TIME; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FIBRILLIZATION; PROTEIN PURIFICATION; REPRODUCIBILITY;

EID: 77950689601     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2010.02.001     Document Type: Article

References (77)

1. Levinthal C. Are there pathways for protein folding?. J. Chim. Phys. 1968, 65:44-45.
2. Karplus M. The Levinthal paradox: yesterday and today. Fold Des. 1997, 2:S69-S75.
3. Dobson C.M. Protein misfolding, evolution, and disease. Trends Biochem. Sci. 1999, 24:329-332.
4. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., Taddei N., Ramponi G., Dobson C.M., Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002, 416:507-511.
5. Stefani M., Dobson C.M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases, and biological evolution. J. Mol. Med. 2003, 81:678-699.
6. Chiti F., Dobson C.M. Amyloid formation by globular proteins under native conditions. Nat. Chem. Biol. 2009, 5:15-22.
7. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75:333-366.
8. Uversky V.N., Li J., Fink A.L. Evidence for a partially folded intermediate in α-synuclein fibril formation. J. Biol. Chem. 2001, 276:10737-10744.
9. Munishkina L.A., Henriques J., Uversky V.N., Fink A.L. Role of protein-water interactions and electrostatics in α-synuclein fibril formation. Biochemistry 2004, 43:3289-3300.
10. Munishkina L.A., Cooper E.M., Uversky V.N., Fink A.L. The effect of macromolecular crowding on protein aggregation and amyloid fibril formation. J. Mol. Recognit. 2004, 17:456-464.
11. Chiti F., Stefani M., Taddei N., Ramponi G., Dobson C.M. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 2003, 424:805-808.
12. Dobson C.M. Protein folding and misfolding. Nature 2003, 426:884-890.
13. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 2005, 289:1-30.
14. Frokjaer S., Otzen D.E. Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov. 2005, 4:298-306.
15. Groenning M., Norrman M., Flink J.M., van de Weert M., Bukrinsky J.T., Schluckebier G., Frokjaer S. Binding mode of thioflavin T in insulin amyloid fibrils. J. Struct. Biol. 2007, 159:483-497.
16. Sen P., Fatima S., Ahmad B., Khan R.H. Interactions of thioflavin T with serum albumins: Spectroscopic analyses. Spectrochim. Acta A 2009, 74:94-99.
17. Biancalana M., Makabe K., Koide A., Koide S. Molecular mechanism of thioflavin-T binding to the surface of beta-rich peptide self-assemblies. J. Mol. Biol. 2009, 385:1052-1063.
18. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D.A., Kondo J., Ihara Y., Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993, 90:11282-11286.
19. Jakes R., Spillantini M.G., Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994, 345:27-32.
20. Weinreb P.H., Zhen W., Poon A.W., Conway K.A., Lansbury P.T. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996, 35:13709-13715.
21. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat. Med. 1998, 4:1318-1320.
22. Conway K.A., Harper J.D., Lansbury P.T. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 2000, 39:2552-2563.
23. Fink A. Factors affecting the fibrillation of α-synuclein, a natively unfolded protein. Misbehaving Proteins: Protein (Mis)folding, Aggregation, and Stability 2007, 265-285. Springer, New York. R. Murphy, A. Tsai (Eds.).
24. Serio T.R., Cashikar A.G., Kowal A.S., Sawicki G.J., Moslehi J.J., Serpell L., Arnsdorf M.F., Lindquist S.L. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science 2000, 289:1317-1321.
25. Sluzky V., Tamada J.A., Klibanov A.M., Langer R. Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc. Natl. Acad. Sci. USA 1991, 88:9377-9381.
26. Kiese S., Pappenberger A., Friess W., Mahler H.-C. Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J. Pharm. Sci. 2008, 97:4347-4366.
27. Cohlberg J.A., Li J., Uversky V.N., Fink A.L. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synuclein in vitro. Biochemistry 2002, 41:1502-1511.
28. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., Di Monte D.A. The herbicide paraquat causes up-regulation and aggregation of α-synuclein in mice. Paraquat and α-synuclein. J. Biol. Chem. 2002, 277:1641-1644.
29. Munishkina L.A., Fink A.L., Uversky V.N. Accelerated fibrillation of α-synuclein induced by the combined action of macromolecular crowding and factors inducing partial folding. Curr. Alzheimer Res. 2009, 6:252-260.
30. Munishkina L.A., Phelan C., Uversky V.N., Fink A.L. Conformational behavior and aggregation of α-synuclein in organic solvents: modeling the effects of membranes. Biochemistry 2003, 42:2720-2730.
31. Uversky V.N., Li J., Bower K., Fink A.L. Synergistic effects of pesticides and metals on the fibrillation of α-synuclein: Implications for Parkinson's disease. Neurotoxicology 2002, 23:527-536.
32. Uversky V.N., Li J., Fink A.L. Pesticides directly accelerate the rate of α-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett. 2001, 500:105-108.
33. Uversky V.N., Li J., Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein: a possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 2001, 276:44284-44296.
34. Yamin G., Glaser C.B., Uversky V.N., Fink A.L. Certain metals trigger fibrillation of methionine-oxidized α-synuclein. J. Biol. Chem. 2003, 278:27630-27635.
35. Yamin G., Uversky V.N., Fink A.L. Nitration inhibits fibrillation of human α-synuclein in vitro by formation of soluble oligomers. FEBS Lett. 2003, 542:147-152.
36. Zhu M., Rajamani S., Kaylor J., Han S., Zhou F., Fink A.L. The flavonoid baicalein inhibits fibrillation of α-synuclein and disaggregates existing fibrils. J. Biol. Chem. 2004, 279:26846-26857.
37. Ehrnhoefer D.E., Bieschke J., Boeddrich A., Herbst M., Masino L., Lurz R., Engemann S., Pastore A., Wanker E.E. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 2008, 15:558-566.
38. Ahmad M.F., Ramakrishna T., Raman B. M. Rao Ch, Fibrillogenic and non-fibrillogenic ensembles of SDS-bound human α-synuclein. J. Mol. Biol. 2006, 364:1061-1072.
39. Necula M., Chirita C.N., Kuret J. Rapid anionic micelle-mediated α-synuclein fibrillization in vitro. J. Biol. Chem. 2003, 278:46674-46680.
40. Kaylor J., Bodner N., Edridge S., Yamin G., Hong D.P., Fink A.L. Characterization of oligomeric intermediates in α-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F α-synuclein. J. Mol. Biol. 2005, 353:357-372.
41. Morris A.M., Watzky M.A., Agar J.N., Finke R.G. Fitting neurological protein aggregation kinetic data via a 2-step, minimal/" Ockham's razor" model: The Finke-Watzky mechanism of nucleation followed by autocatalytic surface growth. Biochemistry 2008, 47:2413-2427.
42. Liu I.H., Uversky V.N., Munishkina L.A., Fink A.L., Halfter W., Cole G.J. Agrin binds α-synuclein and modulates α-synuclein fibrillation. Glycobiology 2005, 15:1320-1331.
43. Goers J., Uversky V.N., Fink A.L. Polycation-induced oligomerization and accelerated fibrillation of human α-synuclein in vitro. Protein Sci. 2003, 12:702-707.
44. Goers J., Manning-Bog A.B., McCormack A.L., Millett I.S., Doniach S., Di Monte D.A., Uversky V.N., Fink A.L. Nuclear localization of α-synuclein and its interaction with histones. Biochemistry 2003, 42:8465-8471.
45. Huang C., Ren G., Zhou H., Wang C.C. A new method for purification of recombinant human α-synuclein in Escherichia coli. Protein Expr. Purif. 2005, 42:173-177.
46. Watzky M.A., Finke R.G. Transition metal nanocluster formation kinetic and mechanistic studies: A new mechanism when hydrogen is the reductant-Slow, continuous nucleation and fast autocatalytic surface growth. J. Am. Chem. Soc. 1997, 119:10382-10400.
47. Ferrone F. Analysis of protein aggregation kinetics. Methods Enzymol. 1999, 309:256-274.
48. Xue W.F., Homans S.W., Radford S.E. Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly. Proc. Natl. Acad. Sci. USA 2008, 105:8926-8931.
49. Zhu M., Fink A.L. Lipid binding inhibits α-synuclein fibril formation. J. Biol. Chem. 2003, 278:16873-16877.
50. Dedmon M.M., Lindorff-Larsen K., Christodoulou J., Vendruscolo M., Dobson C.M. Mapping long-range interactions in α-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J. Am. Chem. Soc. 2005, 127:476-477.
51. Bertoncini C.W., Jung Y.S., Fernandez C.O., Hoyer W., Griesinger C., Jovin T.M., Zweckstetter M. Release of long-range tertiary interactions potentiates aggregation of natively unstructured α-synuclein. Proc. Natl. Acad. Sci. USA 2005, 102:1430-1435.
52. Sung Y., Eliezer D. Residual structure, backbone dynamics, and interactions within the synuclein family. J. Mol. Biol. 2007, 372:689-707.
53. Giasson B.I., Murray I.V., Trojanowski J.Q., Lee V.M. A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly. J. Biol. Chem. 2001, 276:2380-2386.
54. Crowther R.A., Jakes R., Spillantini M.G., Goedert M. Synthetic filaments assembled from C-terminally truncated α-synuclein. FEBS Lett. 1998, 436:309-312.
55. Li J., Uversky V.N., Fink A.L. Conformational behavior of human α-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. Neurotoxicology 2002, 23:553-567.
56. Lashuel H.A., Petre B.M., Wall J., Simon M., Nowak R.J., Walz T., Lansbury P.T.,Jr., A-Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 2002, 322:1089-1102.
57. Necula M., Kuret J. Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J. Biol. Chem. 2004, 279:49694-49703.
58. Wood S.J., Wypych J., Steavenson S., Louis J.C., Citron M., Biere A.L. A-Synuclein fibrillogenesis is nucleation-dependent: Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 1999, 274:19509-19512.
59. Linse S., Cabaleiro-Lago C., Xue W.F., Lynch I., Lindman S., Thulin E., Radford S.E., Dawson K.A. Nucleation of protein fibrillation by nanoparticles. Proc. Natl. Acad. Sci. USA 2007, 104:8691-8696.
60. L. Giehm, C. L. P. Oliveira, G. Christiansen, J. S. Pedersen, D. E. Otzen, SDS-induced fibrillation of α-synuclein: An alternative fibrillation pathway, J. Mol. Biol., in press.
61. Nielsen A.D., Arleth L., Westh P. Analysis of protein-surfactant interactions: A titration calorimetric and fluorescence spectroscopic investigation of interactions between Humicola insolens cutinase and an anionic surfactant. Biochim. Biophys. Acta 2005, 1752:124-132.
62. Nielsen M.M., Andersen K.K., Westh P., Otzen D.E. Unfolding of β-sheet proteins in SDS. Biophys. J. 2007, 92:3674-3685.
63. Andersen K.K., Westh P., Otzen D.E. Global study of myoglobin-surfactant interactions. Langmuir 2008, 24:399-407.
64. Andersen K.K., Oliveira C.L., Larsen K.L., Poulsen F.M., Callisen T.H., Westh P., Pedersen J.S., Otzen D.E. The role of decorated SDS micelles in sub-CMC protein denaturation and association. J. Mol. Biol. 2009, 391:207-226.
65. Otzen D.E., Sehgal P., Westh P. A-Lactalbumin is unfolded by all classes of surfactants but by different mechanisms. J. Colloid Interface Sci. 2009, 329:273-283.
66. Nielsen L., Khurana R., Coats A., Frokjaer S., Brange J., Vyas S., Uversky V.N., Fink A.L. Effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism. Biochemistry 2001, 40:6036-6046.
67. Oosawa F., Asakura S. Thermodynamics of the Polymerization of Protein 1975, Academic Press, New York.
68. Dusa A., Kaylor J., Edridge S., Bodner N., Hong D.P., Fink A.L. Characterization of oligomers during α-synuclein aggregation using intrinsic tryptophan fluorescence. Biochemistry 2006, 45:2752-2760.
69. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 2000, 97:571-576.
70. Goldsbury C.S., Wirtz S., Müller S.A., Sunderji S., Wicki P., Aebi U., Frey P. Studies on the in vitro assembly of Aβ 1-40: Implications for the search for Aβ fibril formation inhibitors. J. Struct. Biol. 2000, 130:217-231.
71. Nesgaard L., Vad B., Christiansen G., Otzen D. Kinetic partitioning between aggregation and vesicle permeabilization by modified ADan. Biochim. Biophys. Acta 2009, 1794:84-93.
72. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., Lansbury P.T. Vesicle permeabilization by protofibrillar α-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 2001, 40:7812-7819.
73. Kim H.J., Chatani E., Goto Y., Paik S.R. Seed-dependent accelerated fibrillation of α-synuclein induced by periodic ultrasonication treatment. J. Microbiol. Biotechnol. 2007, 17:2027-2032.
74. Rivers R.C., Kumita J.R., Tartaglia G.G., Dedmon M.M., Pawar A., Vendruscolo M., Dobson C.M., Christodoulou J. Molecular determinants of the aggregation behavior of α- and β-synuclein. Protein Sci. 2008, 17:887-898.
75. Ferreon A.C., Deniz A.A. A-Synuclein multistate folding thermodynamics: Implications for protein misfolding and aggregation. Biochemistry 2007, 46:4499-4509.
76. Fink A.L. The aggregation and fibrillation of α-synuclein. Acc. Chem. Res. 2006, 39:628-634.
77. Hong D.-P., Fink A.L., Uversky V.N. Structural characteristics of α-synuclein oligomers stabilized by the flavonoid baicalein. J. Mol. Biol. 2008, 383:214-223.